Home » Topics » Musculoskeletal, BioWorld Science

Musculoskeletal, BioWorld Science
RSS

NT-1654 reduces clinical severity of EAMG in rats

July 20, 2018

Daiichi Sankyo and collaborator patent TNSALP inhibitors

July 19, 2018

Topline data presented from phase III trial of tanezumab

July 19, 2018

TAS-05567 selectively inhibits Syk kinase: potential treatment for autoimmune and allergic diseases

July 19, 2018

Audentes Therapeutics presents phase I/II data on AT-132 for XLMTM

July 13, 2018

FDA lifts clinical hold on Invossa trials

July 9, 2018

Bayer initiates first-in-human study with BAY-1830839

July 9, 2018

Neovacs reports phase IIb results for IFN-alpha kinoid in moderate to severe lupus

July 3, 2018

From Adam's rib to Miss Piggy's jaw

July 3, 2018

European Commission approves Xeljanz for active psoriatic arthritis

June 29, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...